CeriBell Price to Free Cash Flow Ratio 2025-2024 | CBLL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

CeriBell price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

CeriBell price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$221.8B
Boston Scientific (BSX)	$151.4B
Stryker (SYK)	$149.1B
EssilorLuxottica (ESLOY)	$125.1B
Medtronic (MDT)	$117.2B
Lonza Group Ag (LZAGY)	$46B
Haleon (HLN)	$43.1B
GE HealthCare Technologies (GEHC)	$40.1B
ResMed (RMD)	$37.1B
Terumo (TRUMY)	$28.9B
Koninklijke Philips (PHG)	$25.6B
Zimmer Biomet Holdings (ZBH)	$22.1B
Insulet (PODD)	$19.4B
Baxter (BAX)	$16.7B
Smith & Nephew SNATS (SNN)	$11.1B
BellRing Brands (BRBR)	$10.1B
Sunny Optical Technology (SNPTF)	$10B
Bio-Rad Laboratories (BIO)	$10B
Demant (WILYY)	$8.7B
Lantheus Holdings (LNTH)	$6.4B
ICU Medical (ICUI)	$4.1B
Prestige Consumer Healthcare (PBH)	$3.9B
Envista Holdings (NVST)	$3.7B
Haemonetics (HAE)	$3.4B
Perrigo (PRGO)	$3.4B
GN Store Nord (GNNDY)	$3B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.9B
Neogen (NEOG)	$2.5B
LeMaitre Vascular (LMAT)	$2.2B